Gene Therapy Breakthrough: Enhanced Immunotherapy for HER2-Positive Cancers

Strategic Insights -

Researchers at the Shiraz University of Medical Sciences in Iran have made a significant breakthrough in the development of gene therapy for HER2-positive cancers. By creating chimeric antigen receptor (CAR) T cells that co-express IL-15, they have demonstrated enhanced immunotherapy efficacy against these aggressive malignancies. The study, published in the journal Molecular Biology Reports, highlights the potential of CAR NK cells in delivering potent antitumor activity.

Key Takeaways:

  • The study aimed to develop anti-HER2 CAR NK cells as a novel therapeutic strategy for cancer immunotherapy, leveraging the promising outcomes of CAR technology-based immunotherapy.
  • The research team successfully generated two distinct CAR NK cell populations: anti-HER2 CAR NK cells and IL-15-secreting anti-HER2 CAR NK cells, both of which demonstrated significantly higher levels of total apoptosis in HER-positive SK-BR-3 cells compared to control groups.
  • IL-15-secreting anti-HER2 CAR NK cells exhibited superior cytotoxic potential compared to their non-secreting counterparts, indicating a promising immunotherapeutic strategy for HER2-positive malignancies.
  • The study's findings suggest that these engineered CAR NK cells hold potential as a novel immunotherapeutic tool for treating HER2-positive cancers.
  • The research has been peer-reviewed and published in the journal Molecular Biology Reports, highlighting its credibility and significance in the field.

Statistics:

  • 53.1% of CD107a expression was significantly higher in CAR NK cells co-cultured with SK-BR-3 cells compared to control groups.
  • 67.4% increase in granzyme B expression was observed in both CAR NK cell types following co-culture with HER2-positive SK-BR-3 cells.
  • 43.2% increase in perforin expression was demonstrated in both CAR NK cell populations following co-culture with HER2-positive SK-BR-3 cells.

Sources:

  • NewsRx. Studies from Shiraz University of Medical Sciences Provide New Data on Gene Therapy [Generation of the augmented IL-15-secreting anti-HER2 chimeric antigen receptor (CAR)-NK cells: an encouraging immunotherapeutic tool]. Cancer Weekly. November 4, 2025; p 63.
  • Molecular Biology Reports. Generation of the augmented IL-15-secreting anti-HER2 chimeric antigen receptor (CAR)-NK cells: an encouraging immunotherapeutic tool. 2025;53(1):3.